These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 31316209)

  • 21. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
    Giuliani E; Vassena L; Cerboni C; Doria M
    Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
    Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
    Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition.
    Song DG; Ye Q; Santoro S; Fang C; Best A; Powell DJ
    Hum Gene Ther; 2013 Mar; 24(3):295-305. PubMed ID: 23297870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34
    Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C
    Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia.
    Wu Z; Zhang H; Wu M; Peng G; He Y; Wan N; Zeng Y
    Biomed Pharmacother; 2021 May; 137():111299. PubMed ID: 33508619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KLF4-mediated upregulation of the NKG2D ligand MICA in acute myeloid leukemia: a novel therapeutic target identified by enChIP.
    Alkhayer R; Ponath V; Frech M; Adhikary T; Graumann J; Neubauer A; von Strandmann EP
    Cell Commun Signal; 2023 May; 21(1):94. PubMed ID: 37143070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MICAgen Mice Recapitulate the Highly Restricted but Activation-Inducible Expression of the Paradigmatic Human NKG2D Ligand MICA.
    Kim Y; Born C; Bléry M; Steinle A
    Front Immunol; 2020; 11():960. PubMed ID: 32582150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance.
    Vulpis E; Loconte L; Peri A; Molfetta R; Caracciolo G; Masuelli L; Tomaipitinca L; Peruzzi G; Petillo S; Petrucci MT; Fazio F; Simonelli L; Fionda C; Soriani A; Cerboni C; Cippitelli M; Paolini R; Bernardini G; Palmieri G; Santoni A; Zingoni A
    J Extracell Vesicles; 2022 Jan; 11(1):e12176. PubMed ID: 34973063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species.
    Dou J; Li L; Guo M; Mei F; Zheng D; Xu H; Xue R; Bao X; Zhao F; Zhang Y
    Int J Nanomedicine; 2021; 16():1231-1244. PubMed ID: 33633448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.
    Zhao P; Yang L; Li X; Lu W; Lu F; Wang S; Wang Y; Hua L; Cui C; Dong B; Yu Y; Wang L
    Cancer Sci; 2020 Jul; 111(7):2234-2247. PubMed ID: 32333709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
    Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
    Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
    Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
    Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
    Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
    [No Abstract]   [Full Text] [Related]  

  • 36. Natural killer cell-activating receptor NKG2D mediates innate immune targeting of allogeneic neural progenitor cell grafts.
    Phillips LK; Gould EA; Babu H; Krams SM; Palmer TD; Martinez OM
    Stem Cells; 2013 Sep; 31(9):1829-39. PubMed ID: 23733329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.
    Sanchez-Correa B; Morgado S; Gayoso I; Bergua JM; Casado JG; Arcos MJ; Bengochea ML; Duran E; Solana R; Tarazona R
    Cancer Immunol Immunother; 2011 Aug; 60(8):1195-205. PubMed ID: 21644031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
    Kikushige Y; Akashi K
    Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
    Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
    Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.
    Schlegel P; Ditthard K; Lang P; Mezger M; Michaelis S; Handgretinger R; Pfeiffer M
    J Immunol Res; 2015; 2015():473175. PubMed ID: 26236752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.